抗血栓形成药物的研究进展  

Research progress of antithrombotic drugs

作　　者：张杰 麻旭州 李慧慧 王淼 ZHANG Jie;MA Xuzhou;LI Huihui;WANG Miao(College of Chemistry and Life Sciences,Zhejiang Normal University,Jinhua 321000;State Key Laboratory of Cardiovascular Disease,Fuwai Hospital,National Center for Cardiovascular Diseases,CAMS&PUMC,Beijing 100037,China)

机构地区：[1]浙江师范大学化学与生命科学学院,浙江金华321000 [2]中国医学科学院、北京协和医学院、国家心血管病中心、阜外医院、心血管疾病国家重点实验室,北京100037

出　　处：《基础医学与临床》2023年第1期183-187,共5页Basic and Clinical Medicine

基　　金：国家重点研发计划(2020YFC2008000);中国医学科学院医学与健康技术创新工程(2017-I2M-1-008,2016-I2M-1-003)。

摘　　要：血栓形成是动脉粥样硬化性心血管疾病患者急性表征(心肌梗死,卒中)的主要直接诱因。在全球范围内,血栓栓塞性疾病的发病率近年来有所增加,患者病死率也随之增加。目前,针对血栓栓塞性疾病,已经发展了几种靶向给药策略,其中包括抗血小板药物和抗凝血药物,随着抗血栓形成药物的研究进展,治疗血栓导致的心血管疾病为患者带来了巨大的潜在效益。Thrombosis is the main direct cause of acute manifestations of atherosclerotic cardiovascular disease(myocardial infarction,stroke).Globally,the incidence of thromboembolic diseases has increased in recent years,accompanied by an increase in patient mortality.Currently,several targeted drug delivery strategies have been developed for thromboembolic diseases,including antiplatelet drugs and anticoagulant drugs.With the development of antithrombotic drugs,the treatment of cardiovascular diseases caused by thrombus shows significant potential benefit for patients.

关 键 词：血栓 药物 抗血小板 抗凝血 

分 类 号：R364.15[医药卫生—病理学]